At our recent automation webinar we explored the need to fill the current innovation gap around bioanalytics for cell-based therapy production as well as where & how to bring these tools in-process.
View this webinar by simply clicking HERE.
At our recent cell & gene therapy event Invetech had a successful workshop addressing the cost-of-therapy challenge. Industry leaders –including Novartis, Celyad and bluebird bio- discussed their visions for a competitive future. We’re now delighted to share with you the video of the whole session.
Bluebird bio and Celgene are developing a CART technology for solid tumours. This autologous platform will have numerous technical challenges to deliver it as safe, cost-effective personalized cancer therapy, particularly as production scales up for late stage trials and real world use. We caught up with Peter Olagunju, Senior Director of Technical Operations at bluebird bio at our Miami Leaders Forum 2017 to pose some questions to him on how the company is facing these difficulties.
A critical look at CAR-T therapeutics
Increasing the capacity, efficiency and robustness of biomanufacturing for multiple late-stage clinical and commercial-scale cell-based products is THE critical challenge for the industry moving forward.
It is crucial that we as an industry come together to drive the evolution and uptake of novel automated tools, guidelines and standards.
This is what our working group is Edinburgh is doing.
This is what we are reflecting upon in our recent blog – where automated methods can be implemented in the autologous CAR-T therapy process.
Check back regularly to catch up with the latest content, or sign up to our e-newsletter here to receive it directly into your inbox.